Introducing Michael Kors Access Wearable Technology: Time for Fashion to Meet the Future

LONDON - Tuesday, September 6th 2016 [ME NewsWire]

(BUSINESS WIRE)-- Michael Kors (NYSE:KORS), a global luxury lifestyle brand, is excited to introduce the MICHAEL KORS ACCESS display smartwatch, part of its new wearable technology accessories line. The line is geared towards the fashion-focused consumer and combines innovative technology with exceptional style from a leader in luxury fashion.
The cutting-edge technology at the heart of the MICHAEL KORS ACCESS smartwatch, which is compatible with both iPhone® and Android™ phones, is made possible through a partnership with Google, using their Android Wear™ smartwatch platform.
Designed to show that technology and social connectivity should be seamless, the MICHAEL KORS ACCESS line, which also includes activity trackers, proves that access can be both glamorous and effortless. “Our customers love fashion and they’re plugged in 24/7,” says Michael Kors. “I think they’ll appreciate having social connectivity and health and fitness tracking all within a great-looking accessory.”
MICHAEL KORS ACCESS smartwatches offer customizable features perfect for our fans:

• Exclusive Michael Kors display watch faces, which change with a swipe—whether it’s a digital chronograph design for the gym or glittering, animated pavé for night
• Hundreds of possible combinations of display face, color and sub dials
• A touchscreen display smartwatch powered by Android Wear that provides:
  • Social media updates and text and email alerts
  • App notifications
  • Smart help from Google
  • Built-in fitness tracking
• Interchangeable leather and silicone wristbands
• Glamorous versions for women and sporty versions for men
• Magnetic charging
• The Qualcomm® Snapdragon™ Wear 2100, a system-on-a-chip (SoC) designed to ensure a highly interactive touch screen experience

“We’re excited to offer our customers smart, great-looking watches that will help them to stay on top of their daily lives while uniquely expressing their personal style,” says John Idol, Chairman and CEO of Michael Kors.
The Michael Kors customer lives a busy, fast-paced life and the MICHAEL KORS ACCESS collection will let him or her stay connected. “From Google Search to smartwatches, Google strives to give you the information you need to stay connected to what matters most,” says David Singleton, VP of Engineering for Android Wear. “MICHAEL KORS ACCESS and Android Wear move the wearables category forward with smart, beautiful watches that help you stay on top of your daily life while expressing your personal style.”
MICHAEL KORS ACCESS will be launched in 18 countries via a global digital and print advertising campaign, including a video featuring Zendaya and Martha Hunt. The video follows the two models on a jam-packed day in New York City—from morning workouts to a glamorous evening party. Throughout the day, Michael Kors Access smartwatches keep them in sync and looking chic—proof that with the right accessory, you really can #AccessItAll. You can watch the video here: https://youtu.be/vV7_aaSKNU0.
The MICHAEL KORS ACCESS smartwatches start at $350 USD. The activity trackers start at $95 USD. Both are available in Michael Kors stores, MichaelKors.com and select department and specialty stores.
For more information, please visit the following:
Michael Kors Access: http://www.michaelkors.com/Access
Destination Kors: http://www.destinationkors.com/
Michael Kors on Facebook: http://www.facebook.com/michaelkors
@MichaelKors on Twitter: http://twitter.com/michaelkors
@MichaelKors on Instagram: http://instagram.com/michaelkors
Michael Kors on Pinterest: http://pinterest.com/michaelkors.com
@MichaelKors on Weibo: http://weibo.com/michaelkors
Search for “Michael Kors” on Weixin and WeChat
Search for “Michael Kors” on LINE Japan
Android Wear™ requires a phone running Android 4.3+ or iOS 8.2+. Supported features may vary between platforms. Visit g.co/wearcheck on your Android phone or iPhone® to see if your device is compatible.
Google, Android and Android Wear are trademarks of Google Inc.
iPhone is a trademark of Apple, Inc. Qualcomm and Snapdragon are trademarks of Qualcomm Incorporated.
About Michael Kors
Michael Kors is a world-renowned, award-winning designer of luxury accessories and ready-to-wear. His namesake company, established in 1981, currently produces a range of products under Michael Kors Collection, MICHAEL Michael Kors and Michael Kors Mens, including accessories, footwear, watches, jewelry, ready-to-wear and a full line of fragrance products. Michael Kors stores are operated, either directly or through licensing partners, in some of the most prestigious cities in the world, including New York, Beverly Hills, Chicago, London, Milan, Paris, Munich, Istanbul, Dubai, Seoul, Tokyo and Hong Kong.
Forward-Looking Statements
This press release contains forward-looking statements. You should not place undue reliance on such statements because they are subject to numerous uncertainties and factors relating to the Company’s operations and business environment, all of which are difficult to predict and many of which are beyond the Company’s control. Forward-looking statements include information concerning the Company’s possible or assumed future results of operations, including descriptions of its business strategy. These statements often include words such as “may,” “will,” “should,” “believe,” “expect,” “seek,” “anticipate,” “intend,” “plan,” “estimate” or similar expressions. The forward-looking statements contained in this press release are based on assumptions that the Company has made in light of management’s experience in the industry as well as its perceptions of historical trends, current conditions, expected future developments and other factors that it believes are appropriate under the circumstances. You should understand that these statements are not guarantees of performance or results. They involve known and unknown risks, uncertainties and assumptions. Although the Company believes that these forward-looking statements are based on reasonable assumptions, you should be aware that many factors could affect its actual financial results or results of operations and could cause actual results to differ materially from those in these forward-looking statements. These factors are more fully discussed in the “Risk Factors” section and elsewhere in the Company’s Annual Report on Form 10-K for the fiscal year ended April 2, 2016 (File No. 001-35368), filed on June 1, 2016 with the U.S. Securities and Exchange Commission.

Photos/Multimedia Gallery Available: http://www.businesswire.com/cgi-bin/mmg.cgi?eid=51413304&lang=en 

---

Contacts

ICR, Inc.
Jean Fontana, 203-682-1214
jean.fontana@icrinc.com
Alecia Pulman, 646-277-1231 (Media)
KorsPR@icrinc.com

---

Permalink: http://me-newswire.net/news/18577/en

Tiotropium Respimat® improved lung function in children with asthma aged 6-17 and is well-tolerated compared to placebo in children aged 1-17

LONDON & INGELHEIM, Germany - Monday, September 5th 2016 [ME NewsWire]

    Tiotropium+olodaterol Respimat® with exercise training and behaviour modification significantly increased exercise capacity compared to placebo1,2
    PHYSACTO® trial data also showed improvements in shortness of breath associated with physical activity for people taking tiotropium+olodaterol Respimat® compared to placebo1
    Even in early chronic obstructive pulmonary disease (COPD) stages, decreasing activity is a strong predictor of disease worsening and increases the risk of disability and death3,4

(BUSINESS WIRE)-- Boehringer Ingelheim today announced the first results from the Phase III PHYSACTO® trial that shows Spiolto® (tiotropium+olodaterol) Respimat®, combined with exercise training, helps people with COPD walk for longer periods of time compared to those receiving placebo.1,2 All participants of the trial were enrolled in a self-management behaviour modification programme, which provided health education and skills to help them better manage their disease.1,2,5 These data were presented today at the European Respiratory Society (ERS) International Congress 2016 in London.

After 8 weeks, in the tiotropium+olodaterol Respimat® combined with exercise training arm, exercise capacity in people with moderate to severe COPD significantly increased by 45.8 percent (p<0.001) compared to those receiving placebo with no exercise training (356 vs. 244 seconds respectively).2

“It is vital for people with COPD to stay active as this may help slow the progression of disease burden and reduce its impact on health,” said study investigator Professor Thierry Troosters, Head of the Research Group for Cardiovascular and Respiratory Rehabilitation, University of Leuven, Belgium. “This new study is the first to demonstrate that a holistic approach to COPD management, which includes behaviour modification enriched with exercise training and effective long-acting bronchodilator therapy, can improve exercise capacity, reduce shortness of breath and difficulty associated with daily activities.”

Additional PHYSACTO® results showed that even without exercise training, there was a significant improvement (29.2 percent; p<0.05) in exercise capacity in the tiotropium+olodaterol Respimat® arm compared to placebo (315 vs. 244 seconds respectively).2 Exercise capacity was measured by the length of time people with COPD could walk in an Endurance Shuttle Walking Test.2 This measures how far someone can walk at a standard speed without stopping for a rest.6 Furthermore, tiotropium+olodaterol Respimat® was shown to reduce shortness of breath (dyspnoea) associated with physical activity, compared to placebo.1

COPD is a serious but manageable lung disease, which is estimated to affect 210 million patients worldwide.7 Even in the early stages of COPD, people suffer from breathlessness during daily activities.4 To avoid shortness of breath, people with COPD often reduce the amount of physical activity they undertake and do less of their daily activities.4 This reduction in physical activities has a significant negative impact on their quality of life and can lead to their condition worsening.4

The PHYSACTO trial (NCT02085161) was designed to assess the effect of COPD maintenance therapy alone or in combination with supervised exercise training on exercise capacity and physical activity outcomes, including the amount of physical activity and perceived difficulties.1,2 The participants were randomised into groups, which received either tiotropium+olodaterol Respimat® with and without exercise training, or tiotropium Respimat® alone, or placebo.2 A 12-week self-management behaviour modification programme was included for all four groups to provide an optimal environment for translating improvements in exercise capacity into increases in daily activity.5 The self-management behaviour modification programme included strategies for participants to help them exercise – including a pedometer (a device to count steps) and education to support their COPD management plan.5

These new data build on results from the MORACTO® and TORRACTO® 1&2 studies that show tiotropium+olodaterol Respimat® significantly improves exercise endurance time vs. placebo.8,9 The PHYSACTO® trial is part of the large-scale TOviTO® Phase III clinical trial programme investigating the efficacy and safety of tiotropium+olodaterol Respimat® in COPD.

For ‘Notes to Editors’ and ‘References’ please visit: https://www.boehringer-ingelheim.com/press-release/New_Data:_Spiolto_Respimat_significantly_improves_exercise_capacity_in_people_with_COPD



This Smart News Release features multimedia. View the full release here: http://www.businesswire.com/news/home/20160905005444/en/



To view the Understanding COPD graphic, please click here

Contacts

Boehringer Ingelheim

Corporate Communications

Media + PR

Carolin Grob

Boehringer Ingelheim

Email: carolin.grob@boehringer-ingelheim.com

Phone: +49 (6132) 77-182603

Fax: +49 (6132) 77-6601

Email: press@boehringer-ingelheim.com

or

More information

www.boehringer-ingelheim.com









Permalink: http://www.me-newswire.net/news/18585/en

TCL to Bring State-of-the-Art LCD Display Technologies to IFA 2016

BERLIN - Friday, September 2nd 2016 [ME NewsWire]

(BUSINESS WIRE)-- TCL Corporation (SZSE: 000100), a leading manufacturer of consumer electronics and provider of Internet application services, will exhibit its 8K UHD Curved TV and a full range of other latest TVs and technologies at Booth 102 - Hall 21 of the 56th Internationale Funkausstellung (IFA) in Berlin from September 2nd to 7th, 2016.

TCL has brought a lineup of its latest LCD TVs including the new flagship QUHD TV Xclusive X1 and the TCL “Cityline” Series, to cater for the diversified demands of customers. Among them, the 65” 8K UHD Curved TV is definitely another eye-catcher, featuring a panel produced by China Star Optoelectronics Technology (CSOT) which offers eight times the pixel count of full HD resolution and active 3D function. This 8K prototype will seriously blast the eyeballs of visitors because it displays an extra level of razor sharp detail that is way better than a 4K screen.

TCL will be demonstrating its efforts to gain a foothold in the high-end TV segment. Commenting on TCL’s overseas strategy, Tomson Li, Chairman and CEO of TCL Corporation, said, “We have been investing heavily in innovation to create better TV products. We believe innovation will be rewarding. It will bring us to a new horizon and our users a better experience. We welcome all visitors to experience our innovative offerings at IFA.”

As the LCD TVs have been pursuing larger sizes and higher resolutions, high-end displays play an essential role for TCL to obtain a competitive edge in the LCD TV industry. By actively making strategical vertical integration with upstream display supplier CSOT, TCL has been able to gain a technological advantage and expand its global presence in the high-end LCD display market.

CSOT currently owns two Gen 8.5 and one Gen 6 LCD production lines, which can produce panels as large as 55". On August 29, just days before IFA 2016, TCL announced that the company, its subsidiary CSOT and the local government will jointly invest RMB 46.5 billion (US$ 6.9 billion) to build a production line for Gen 11 TFT-LCD and AMOLED displays, which will start mass production in July 2019. The production line, when completed, will be able to produce 43", 65", 70" (21:9), 75" LCD displays, ultra-large public displays as well as OLED displays, and enable TCL to enhance its portfolio in terms of large-sized LCD displays and help boost the company’s comprehensive competitiveness in LCD display business.

IFA 2016 comes at a special time for TCL, for this year marks the 35th anniversary of the Corporation growing from a local joint venture to a global giant in home appliances. The company came in 3rd in the world ranking of the LCD TV market and 5th in the world’s mobile phone market. Also it is now one of the 10 largest tablet manufacturers.

About TCL Multimedia

Headquartered in China, TCL Multimedia Technology Holdings Limited (HKSE: 01070) is one of the leading players in the global TV industry, engaged in the research and development, manufacturing and distribution of consumer electronic products. Through a new product-and-user-oriented business model that focuses primarily on a “double +” strategy which includes “intelligence + Internet” and “products + services” as the main direction, striving to become a “global entertainment technology enterprise” that provides integrated entertainment solutions to customers.    

Contacts

TCL Multimedia

Jolin Shang, +86-139-2467-9051

Jolin.shang@tcl.com









Permalink: http://www.me-newswire.net/news/18570/en

IMST launches the new version of the 3D EM Design Suite EMPIRE XPU

KAMP-LINTFORT, Germany - Tuesday, September 6th 2016 [ME NewsWire]

(BUSINESS WIRE)-- IMST is pleased to present the brand new edition of the leading 3D electromagnetic field (EM) Design Suite EMPIRE XPU, based on the powerful Finite Difference Time Domain Method (FDTD). The unique XPU technology guarantees a superior performance for a wide range of applications such as antennas, microwave circuits, components, chip design, medical equipment and much more.

Designing complex modules with highly integrated RF frontends for wireless communication, multimedia entertainment, and 5G mobile applications, for example, can be a real challenge for EM solvers but becomes an easy task with EMPIRE XPU.

The key features of the new edition are:

+ Intuitive 3D design mode

You can easily create and edit sophisticated models in 3D with little or no effort. The 3D design mode allows user friendly modeling and supports unlimited local coordinate systems. It perfectly complements the 2D design mode which has superior editing functionalities for planar multilayer assemblies.

+ Data exchange

EMPIRE XPU supports now all industry standard CAD formats, for example ODB++, ACIS, CATIA, IGES, and STEP, and supports direct data exchange between different field solvers.

+ Cloud computing

The Amazon Elastic Compute Cloud can be easily directly accessed via an encrypted connection from the EMPIRE simulation control. The EC2 cloud provides worldwide a large selection of instance types fitting all simulation needs from small single core PCs up to large 64 core workstations with 2 TB main memory.

Demo videos and tutorials are available at

https://www.youtube.com/channel/UCb38NsUTmqSSL5IWNG7vPhg

An evaluation version of EMPIRE XPU 7.50 can be downloaded free of charge at

http://empire.de/page45.html

For more information about Empire XPU, please visit

http://www.empire.de/

Contacts

IMST

Ms. Birthe Jungbluth

Email: marketing@imst.de

Tel. +49 2842 981 0









Permalink: http://www.me-newswire.net/news/18583/en

New Data: Spiolto® Respimat® significantly improves exercise capacity in people with COPD

LONDON & INGELHEIM, Germany - Monday, September 5th 2016 [ME NewsWire]

    Tiotropium+olodaterol Respimat® with exercise training and behaviour modification significantly increased exercise capacity compared to placebo1,2
    PHYSACTO® trial data also showed improvements in shortness of breath associated with physical activity for people taking tiotropium+olodaterol Respimat® compared to placebo1
    Even in early chronic obstructive pulmonary disease (COPD) stages, decreasing activity is a strong predictor of disease worsening and increases the risk of disability and death3,4

(BUSINESS WIRE)-- Boehringer Ingelheim today announced the first results from the Phase III PHYSACTO® trial that shows Spiolto® (tiotropium+olodaterol) Respimat®, combined with exercise training, helps people with COPD walk for longer periods of time compared to those receiving placebo.1,2 All participants of the trial were enrolled in a self-management behaviour modification programme, which provided health education and skills to help them better manage their disease.1,2,5 These data were presented today at the European Respiratory Society (ERS) International Congress 2016 in London.

After 8 weeks, in the tiotropium+olodaterol Respimat® combined with exercise training arm, exercise capacity in people with moderate to severe COPD significantly increased by 45.8 percent (p<0.001) compared to those receiving placebo with no exercise training (356 vs. 244 seconds respectively).2

“It is vital for people with COPD to stay active as this may help slow the progression of disease burden and reduce its impact on health,” said study investigator Professor Thierry Troosters, Head of the Research Group for Cardiovascular and Respiratory Rehabilitation, University of Leuven, Belgium. “This new study is the first to demonstrate that a holistic approach to COPD management, which includes behaviour modification enriched with exercise training and effective long-acting bronchodilator therapy, can improve exercise capacity, reduce shortness of breath and difficulty associated with daily activities.”

Additional PHYSACTO® results showed that even without exercise training, there was a significant improvement (29.2 percent; p<0.05) in exercise capacity in the tiotropium+olodaterol Respimat® arm compared to placebo (315 vs. 244 seconds respectively).2 Exercise capacity was measured by the length of time people with COPD could walk in an Endurance Shuttle Walking Test.2 This measures how far someone can walk at a standard speed without stopping for a rest.6 Furthermore, tiotropium+olodaterol Respimat® was shown to reduce shortness of breath (dyspnoea) associated with physical activity, compared to placebo.1

COPD is a serious but manageable lung disease, which is estimated to affect 210 million patients worldwide.7 Even in the early stages of COPD, people suffer from breathlessness during daily activities.4 To avoid shortness of breath, people with COPD often reduce the amount of physical activity they undertake and do less of their daily activities.4 This reduction in physical activities has a significant negative impact on their quality of life and can lead to their condition worsening.4

The PHYSACTO trial (NCT02085161) was designed to assess the effect of COPD maintenance therapy alone or in combination with supervised exercise training on exercise capacity and physical activity outcomes, including the amount of physical activity and perceived difficulties.1,2 The participants were randomised into groups, which received either tiotropium+olodaterol Respimat® with and without exercise training, or tiotropium Respimat® alone, or placebo.2 A 12-week self-management behaviour modification programme was included for all four groups to provide an optimal environment for translating improvements in exercise capacity into increases in daily activity.5 The self-management behaviour modification programme included strategies for participants to help them exercise – including a pedometer (a device to count steps) and education to support their COPD management plan.5

These new data build on results from the MORACTO® and TORRACTO® 1&2 studies that show tiotropium+olodaterol Respimat® significantly improves exercise endurance time vs. placebo.8,9 The PHYSACTO® trial is part of the large-scale TOviTO® Phase III clinical trial programme investigating the efficacy and safety of tiotropium+olodaterol Respimat® in COPD.

For ‘Notes to Editors’ and ‘References’ please visit: https://www.boehringer-ingelheim.com/press-release/New_Data:_Spiolto_Respimat_significantly_improves_exercise_capacity_in_people_with_COPD



This Smart News Release features multimedia. View the full release here: http://www.businesswire.com/news/home/20160905005444/en/



To view the Understanding COPD graphic, please click here

Contacts

Boehringer Ingelheim

Corporate Communications

Media + PR

Carolin Grob

Boehringer Ingelheim

Email: carolin.grob@boehringer-ingelheim.com

Phone: +49 (6132) 77-182603

Fax: +49 (6132) 77-6601

Email: press@boehringer-ingelheim.com

or

More information

www.boehringer-ingelheim.com









Permalink: http://www.me-newswire.net/news/18585/en

Lenovo Reveals the Yoga™ Book – the 2-in-1 tablet for Productivity and Creativity

Yoga Book Re-Examines How a Tablet Should Look and Act, with Never-Before-Seen Features Such as an Instant Halo Keyboard and a Dual-Use Stylus That Writes on Paper and Screen

BERLIN, Germany - Thursday, September 1st 2016 [ME NewsWire]

    The Yoga Book harnesses the best of the tablet while introducing new productivity and creative hardware and software, with halo keyboard feature, real-pen accessory and Book UI.
    The Yoga Book’s halo keyboard feature weaves software and hardware into one interface, allowing for a typing experience that far surpasses conventional tablets and matches that of physical keyboards.
    Drawing inspiration from the elegance and simplicity of notebooks, the Yoga Book’s real-pen accessory allows users to write and draw with pen and paper while instantly digitizing their notes and sketches.
    The Yoga Book’s thin and light design, 15-hour battery life and 360-degree watchband hinge gives on-the-go tablet users the freedom to write and draw anywhere, matching the mobility of a smartphone without having to carry a laptop or detachable.
    The Yoga Book, available on both Android and Windows, is the world’s thinnest and lightest 2-in-1 tablet, and a direct response to user demands for a better experience for productivity on tablets.

 (BUSINESS WIRE)-- Lenovo (SEHK:0992)(Pink Sheets:LNVGY) today launched the Yoga Book, the world’s thinnest and lightest 2-in-1[1] tablet, designed for unmatched productivity while on-the-go. Built for mobility and to solve the most common challenge among tablet users – how to achieve productivity and entertainment in one device – the Yoga Book is a tablet that looks and acts like no other. Up until now, we’ve been using tablets in ways we weren’t meant to: for productivity, for example, which becomes painful when typing or applying a stylus onto a touch screen that you’re using on-the-go. The Yoga Book removes that difficulty by taking the fundamental building blocks from the DNA of what makes a great tablet – namely portability, long battery life and a rich app ecosystem – and entwines it into a strand of creativity and productivity through a suite of powerful new hardware and software features, including:

    The instant halo keyboard
    The dual-use stylus that writes on paper and screen
    The productivity-driven Book U



Quote

“We set out to redefine the tablet category conundrum, namely that consumers no longer separate their activities into productivity and entertainment – it all blends together, and so should the device they use,” said Jeff Meredith, vice president and general manager, Android and Chrome Computing, Lenovo. “The Yoga Book introduces keyboard and handwriting input capability in an elegantly simple, unconventionally slender tablet design. We believe our unique design will offer tablet, 2-in-1 and traditional notebook buyers a first-of-its-kind option for evolving usage trends.”
     

[1] Based on Lenovo’s internal analysis as of 8/18/16 of 10.1” or greater 2-in-1 computers (sold with keyboard) using Windows, Android, Chrome or OSX sold by major competitors shipping >1 million units worldwide annually; measured with keyboard attached in closed position.

Ultra-Thin and Light

With two panels that open up like an ultrathin notebook, the Yoga Book is unconventionally slender and light years removed from the tablet that you’re accustomed to using on the go or while sitting in your home. As the world’s thinnest 2-in-1, the Yoga Book is 9.6mm closed, tapering to 4.05mm at its slimmest edge – a thickness of just under three pennies. And because it’s also the lightest 2-in-1 in the world at 690 grams (1.52 pounds), the Yoga Book is made to match the mobility of a smartphone, so you can easily hold and carry, just like a book. Users who take the Yoga Book with them on day trips have the option to work anywhere – on a busy commute, in a packed waiting room or on a crowded countertop – if and when they feel like it, thanks to the thin and light design, 15-hour[2] battery life and a watchband hinge that folds 360 degrees. And if users don’t feel like working, they’ll have a top-of-the-line entertainment tablet to keep them company, with a 10.1-inch IPS FHD screen, high-quality sound enhanced with Dolby Atmos® and 64GB of memory.

Instant Halo Keyboard

The Yoga Book’s first productivity feature is also what makes the thin and light design possible: the halo keyboard, a full touch screen backlit keyboard that weaves software and hardware into one fluid interface. The touch screen is made with glass that was meticulously chosen to give a rough, matte feel and finish, along with anti-glare coating to ensure the best possible touch-typing experience. The keyboard lacks any physical keys, showing up as a solid white outline on the Yoga Book’s second panel only when it’s needed. The halo keyboard constantly ‘learns about and adapts to’ the typing habits of its user, with built-in prediction and artificial learning software. This software also allows for continuous optimization. Along with built-in, sensitive haptic technology, which enables touch feedback to guide typing and reduce mistakes, the halo keyboard far surpasses the typing experience and speed of a normal tablet, and is comparable with that of a physical keyboard.

Real-Pen Accessory – Dual Use Stylus

The flush surface of the halo keyboard feature also allows for a few additional uses when paired with the Yoga Book’s standard real-pen accessory, a dual-use stylus. Inspired by the elegance and simplicity of real notebooks, Yoga Book is an acknowledgement that we all still love to write and draw on paper. Users can now write with the real-pen accessory that holds real ink tips onto a piece of paper or notepad covering the multi-use keyboard panel, or as a stylus when applied straight onto the panel. Everything they create, from doodles and drawings to notes, is instantly digitized and saved with the Lenovo note-saving app.[3] Roughly the size of a conventional ink pen, the real-pen accessory is powered by Wacom feel™ IT technologies to work with the state-of-the-art electro-magnetic resonance (EMR) film housed within the multi-use keyboard, which enables this real-time digitization.

The multi-use keyboard and real-pen accessory recreate the natural feel of drawing flat on a paper surface instead of directly onto a computer screen, without having to block parts of the art work with the hand or stylus. Or you can draw directly on the screen as well, depending on preference. The real-pen accessory can draw with the precision of a pencil or paintbrush, with 2,048 pressure levels and 100-degree angle detection. In addition, you’ll never have to charge or replace it – the real-pen accessory doesn’t require batteries and its ink can be replaced with standard ink tips, just like that of a conventional pen.

[2] Android edition; based on a mixed use profile that includes online browsing, playing music and video, reading, drawing and typing. Windows edition offers 13 hours battery life. Actual results will vary, and depend on numerous factors including product configuration and usage, software, operating conditions, wireless functionality, power management settings, screen brightness and other factors. The maximum capacity of the battery will naturally decrease with time and usage.

[3] Available only on Android. Similar to OneNote on Yoga Book with Windows.

Book UI and Hinge

As a 2-in-1 that weaves together both hardware and software, Yoga Book truly brings work and play into one tablet through the Book UI, the Yoga Book’s specially adapted Android 6.0 operating system that draws from the best UI features of laptops and tablets. The Book UI allows several apps to run at once through multiple windows that can be pinned, maximized or minimized, as well as a taskbar that keeps track of your apps and common Windows keyboard shortcuts and action keys. This additional new workload is easily handled by the Yoga Book’s powerful Intel® Atom™ X5 processor and 4GB of memory. And Windows users also have the option to work on that platform, as the Yoga Book is available on Windows 10.

Constructed from a combination of magnesium and aluminium alloys, the Yoga Book is robust in build and guaranteed to turn heads. As with all Yoga products, it has the distinctive watchband-style hinge. This time, the hinge is engineered to be smaller and features a custom-made three-axis hinge, with 130 different mechanical pieces comprising five different materials. Lab tested more than 25,000 times, the Yoga Book form offers a smooth, seamless transition between the four modes – Browse, Watch, Create and Type. The Yoga Book with Android is available in Gold or Gunmetal, while the Yoga Book with Windows comes in Carbon Black.

Pricing and Availability4

Pricing for the Yoga Book will start at €499 for the Android version and €599 for the Windows version. Pricing and availability may vary from country to country. All will be globally available beginning in September. In the US, the Yoga Book will be sold online by the end of October.

Discover more at www.lenovo.com/lenovolaunch and www.lenovo.com/ifa.

To stay updated on the latest Lenovo IFA News, follow #LenovoLaunch and #LenovoIFA on Twitter, Facebook and Instagram.

For Moto news visit: http://motorola-blog.blogspot.com/2016/08/picture-perfect-new-moto-z-play-and.html

For additional IFA news visit:

    Yoga 910 and Yoga Tab 3 Plus press release
    Miix 510 blog post
    Yoga Tab 3 Plus blog post

For additional details on the Yoga Book visit:

    Yoga Book: The first tablet for natural sketching and note-taking
    Yoga Book: Projecting a halo effect on the next generation of keyboards
    Yoga Book: The world’s thinnest and lightest 2-in-1

Lenovo (SEHK:0992)(Pink Sheets:LNVGY) is a $46 billion global Fortune 500 company and a leader in providing innovative consumer, commercial, and enterprise technology. Our portfolio of high-quality, secure products and services covers PCs (including the legendary Think and multimode YOGA brands), workstations, servers, storage, smart TVs and a family of mobile products like smartphones (including the Moto brand), tablets and apps. Join us on LinkedIn, follow us on Facebook or Twitter (@Lenovo) or visit us at www.lenovo.com.

[4] Prices do not include tax or shipping or options and are subject to change without notice; additional terms and conditions apply. Reseller prices may vary. On-shelf dates may vary by geography and products may only be available in selected markets. All offers subject to availability. Lenovo reserves the right to alter product offerings, features and specifications at any time without notice.



Contacts

Lenovo

Herman Cheng

hcheng1@lenovo.com









Permalink: http://www.me-newswire.net/news/18558/en

Simple blood test combined with exacerbation history may help to identify when to add ICS to COPD treatment

LONDON & INGELHEIM, Germany - Monday, September 5th 2016 [ME NewsWire]

    New WISDOM post-hoc subanalysis suggests the number of people with COPD receiving additional exacerbation risk benefit from ICS may be smaller than previously defined1,2
    People with a combination of frequent exacerbations and a raised level of eosinophils (≥400 cells/µL) may get additional exacerbation risk reduction from ICS on top of tiotropium and salmeterol1,3
    These data inform the clinical understanding that only a minority of people with COPD may benefit from ICS1,3

(BUSINESS WIRE)-- Boehringer Ingelheim today announced a new post-hoc subanalysis of the WISDOM study that suggests only 4 out of 100 people with chronic obstructive pulmonary disease (COPD), who have a history of frequent exacerbations and raised eosinophil levels (≥400 cells/µL), may further benefit by adding inhaled corticosteroids (ICS, fluticasone propionate 500µg twice daily) to Spiriva® (tiotropium 18μg once daily) and a long-acting beta2-agonist (LABA, salmeterol 50μg twice daily) with regard to reducing exacerbation risk.1,3 Eosinophils, which are a type of white blood cell, are assessed as part of a routine blood test.4 This new post-hoc subanalysis was presented today at the European Respiratory Society (ERS) International Congress 2016 in London.

“New results from the WISDOM study indicate that using ICS as part of a triple therapy regimen in COPD maintenance treatment reduces the likelihood of an exacerbation for a smaller number of people than previously thought. It challenges our current understanding of the appropriate use of ICS in COPD maintenance therapy,” said study investigator Professor Peter Calverley, Professor of Pulmonary Medicine, University of Liverpool, UK. “These study results add important information to a debate that has potentially wide-ranging implications for the future treatment of people with COPD.”

Exacerbations significantly contribute to the impact of COPD, often leading to the person being admitted to a hospital,5 and can increase the risk of death.6 The Global Initiative for Chronic Obstructive Lung Disease (GOLD), which is a collaboration between the World Health Organization and the US National Institutes of Health, recommends the use of ICS-containing therapy only in people with COPD who have severe to very severe lung function impairment and/or are at high risk of exacerbations (GOLD C/D) or who have had a hospitalisation7 – the patient population studied in WISDOM. However, ICS are widely used outside of GOLD treatment recommendations in combination with bronchodilators, such as tiotropium and LABAs, in the treatment of COPD.8

This new post-hoc subanalysis suggests that by combining history of frequent exacerbations (two or more exacerbations in the past twelve months) with raised blood eosinophil levels of ≥400 cells/µL, healthcare providers may more precisely identify the minority of people with COPD who could experience a further exacerbation risk reduction from ICS (fluticasone propionate) on top of tiotropium and a LABA (salmeterol).1,3

This finding further builds on an earlier post-hoc analysis of the WISDOM trial, which evaluated blood eosinophil levels alone, and indicated that people with blood eosinophil levels higher than ≥300 cells/µL had an additional exacerbation reduction from ICS (fluticasone propionate) on top of tiotropium and a LABA (salmeterol).2

The 52-week WISDOM study (NCT00975195) evaluated the effect of ICS (fluticasone propionate) withdrawal in people with severe to very severe COPD having a history of exacerbation, while receiving tiotropium and a LABA (salmeterol).9 The patient population of the WISDOM trial represents approximately 20 percent of the normal COPD patient population10 and only 4 percent of this population were known to have a history of frequent exacerbations (two or more exacerbations in the past twelve months) with raised blood eosinophil levels of ≥400 cells/µL.1,3

“Boehringer Ingelheim is committed to continuing scientific research that informs the optimal treatment of people with COPD. These findings add to our understanding of the factors that should be considered by healthcare providers when deciding a treatment regimen for people with COPD – specifically when to add an ICS,” said Dr William Mezzanotte, Vice President and Head of Respiratory Medicine at Boehringer Ingelheim. “In addition, these findings highlight the importance of further investigation and discussion of this topic.”

In the WISDOM study population, complete ICS (fluticasone propionate) withdrawal was associated with a small reduction in trough FEV1.9 The earlier post-hoc analysis showed overall no relationship between blood eosinophil count and change in lung function with ICS (fluticasone propionate) withdrawal.2 However, the latest post-hoc subanalysis indicated a relevant reduction in trough FEV1 in the small subgroup of people with high eosinophil count and frequent exacerbations.11

COPD is a serious but manageable lung disease, which is estimated to affect 210 million people worldwide.12 Total deaths from COPD are projected to increase by more than 30 percent in the next 10 years; COPD is predicted to become the third leading cause of death globally by 2030.13

For ‘Notes to Editors’ and ‘References’ please visit: https://www.boehringer-ingelheim.com/press-release/simple-blood-test-help-to-identify-when-to-add-ics

This Smart News Release features multimedia. View the full release here: http://www.businesswire.com/news/home/20160905005424/en/

Contacts

Boehringer Ingelheim

Corporate Communications

Media + PR

Carolin Grob

Email: carolin.grob@boehringer-ingelheim.com

Phone: +49 (6132) 77-182603

Fax: +49 (6132) 77-6601

Email: press@boehringer-ingelheim.com

www.boehringer-ingelheim.com









Permalink: http://me-newswire.net/news/18584/en